Interestingly, the large reductions in both fasting and non-fasting glucose levels in humans and rats treated with GPR40 agonists were accompanied by very modest increases insulin secretion that were observed in diabetics only under conditions of hyperglycemia (i.e. glucose challenge). Here, FFAR1 is linked to diabetes mellitus.